FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Accepts NDA for Glaucoma Drug

[ Price : $8.95]

FDA accepts for review a Bausch & Lomb and Nicox NDA for Vesneo (latanoprostene bunod ophthalmic solution 0.024%), an intraocular ...

FDA Approves Taiho NDA for Colorectal Cancer

[ Price : $8.95]

FDA approves a Taiho Oncology NDA for Lonsurf (trifluridine and tipiracil), a combination drug for use in patients with an advance...

FDA Grants Alcobra Fast Track for Metadoxine

[ Price : $8.95]

FDA grants Alcobra Ltd. fast track status metadoxine extended release for treating Fragile X Syndrome.

FDA Evaluating Tramadol-related Breathing Adverse Event

[ Price : $8.95]

FDA says it is investigating the pain drug tramadol and its use in children aged 17 years and younger because of a report of slowe...

Panel to Discuss Vaccines for Pregnant Women

[ Price : $8.95]

Federal Register Notice: FDAs Vaccines and Related Biological Products Advisory Committee will meet 11/13 to discuss vaccines admi...

Selectors Sought for Patient Engagement Panel

[ Price : $8.95]

Federal Register Notice: FDA seeks participants for selecting consumer representatives for the Patient Engagement Advisory Committ...

FDA Breakthrough Not Really a Breakthrough: JAMA Authors

[ Price : $8.95]

Carnegie Mellon researchers say FDAs use of the term breakthrough when discussing the approval of new drugs could be misleading to...

FDA Priority Review for Amgen sNDA for Kyprolis

[ Price : $8.95]

FDA accepts for priority review an Amgen supplemental NDA for Kyprolis (carfilzomib) for injection for patients with relapsed mult...

Ex-Merck General Counsel Kuhlik Joins FDA

[ Price : $8.95]

Former Merck general counsel Bruce Kuhlik joins FDA as senior advisor to the commissioner.

FDA Accepts BLA for Primary Immunodeficiency Therapy

[ Price : $8.95]

FDA accepts for review an ADMA Biologics BLA for RI-002, and investigational therapy for treating primary immunodeficiency patient...